Sagent Pharmaceuticals Inc., a provider of specialty pharmaceutical products with a specific emphasis on the injectables market, has named Allan Oberman as chief executive officer and a member of the board of directors, effective immediately upon receipt of a U.S. work visa.

“Allan is a proven leader with impeccable credentials and strategic instincts that will serve Sagent well as we enter our next phase of growth,” said Robert Flanagan, chairman of Sagent’s board of directors. “Allan has deep knowledge and extensive experience in the global generic market. His proven ability to build value while communicating a clear and consistent vision will enable him to provide strong leadership as we look to capitalize on what we believe are significant market opportunities over the coming years. The board is confident that Allan is uniquely qualified to refine our strategy and unify the company around a global plan to accelerate growth.”

Mr. Oberman most recently served as president and chief executive officer of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd., from November 2012 until December 2014.